{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Onivyde", "query": { "intervention": "Onivyde" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 56, "total_pages": 6, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Onivyde&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-04T01:33:46.401Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03207724", "title": "Study of Onivyde and 5-FU in Combination With Xilonix for Pancreatic Cancer With Cachexia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pancreatic Cancer", "Cachexia", "Weight Loss" ], "interventions": [ { "name": "Xilonix plus Onivyde and 5FU", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Andrew Hendifar, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2017-10-16", "completion_date": "2020-10-27", "has_results": false, "last_update_posted_date": "2020-12-30", "last_synced_at": "2026-09-04T01:33:46.401Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03207724" }, { "nct_id": "NCT06219941", "title": "AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gastric Cancer", "Gastroesophageal Junction Cancer", "Biliary Tract Cancer", "Pancreatic Ductal Adenocarcinoma" ], "interventions": [ { "name": "AZD0901", "type": "DRUG" }, { "name": "5-Fluorouracil", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "l-leucovorin", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Nanoliposomal Irinotecan", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 226, "start_date": "2023-12-13", "completion_date": "2027-06-28", "has_results": false, "last_update_posted_date": "2026-07-29", "last_synced_at": "2026-09-04T01:33:46.401Z", "location_count": 7, "location_summary": "Orange, California • Palo Alto, California • Santa Rosa, California + 4 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Santa Rosa", "state": "California" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Commack", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06219941" }, { "nct_id": "NCT07060014", "title": "NALIRIFOX (Nal-IRI Plus 5-FU/LV Plus Oxaliplatin) as First-Line Treatment for Patients With Advanced Small Intestine and Appendiceal Cancers", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Small Intestine Cancer", "Appendiceal Cancers" ], "interventions": [ { "name": "Patients will be treated with NALIRIFOX (liposomal irinotecan 50 mg/m2 + 5-FU 2400 mg/m2 + LV 400 mg/m2 + oxaliplatin 60 mg/m2, IV) every 2 weeks for 12 months", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "The Methodist Hospital Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2025-07-18", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2025-07-11", "last_synced_at": "2026-09-04T01:33:46.401Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07060014" }, { "nct_id": "NCT03739801", "title": "MM-398 and Ramucirumab in Treating Patients With Gastric Cancer or Gastroesophageal Junction Adenocarcinoma", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Locally Advanced Unresectable Gastric Adenocarcinoma", "Metastatic Gastroesophageal Junction Adenocarcinoma", "Metastatic Unresectable Gastric Adenocarcinoma", "Unresectable Gastroesophageal Junction Adenocarcinoma", "Gastric Adenocarcinoma", "Gastroesophageal Junction Adenocarcinoma" ], "interventions": [ { "name": "Liposomal Irinotecan", "type": "DRUG" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Ramucirumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "OTHER", "BIOLOGICAL" ], "sponsor": "University of Southern California", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2020-04-06", "completion_date": "2023-04-06", "has_results": false, "last_update_posted_date": "2020-03-27", "last_synced_at": "2026-09-04T01:33:46.401Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03739801" }, { "nct_id": "NCT03554707", "title": "SGT-53 in Children With Recurrent or Progressive CNS Malignancies", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Childhood CNS Tumor" ], "interventions": [ { "name": "SGT-53", "type": "GENETIC" }, { "name": "Radiation", "type": "RADIATION" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "GENETIC", "RADIATION", "DRUG" ], "sponsor": "SynerGene Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "21 Years", "sex": "ALL", "summary": "1 Year to 21 Years" }, "enrollment_count": 0, "start_date": "2022-06-01", "completion_date": "2022-06-01", "has_results": false, "last_update_posted_date": "2026-05-08", "last_synced_at": "2026-09-04T01:33:46.401Z", "location_count": 1, "location_summary": "Washington D.C., District of Columbia", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03554707" }, { "nct_id": "NCT04390399", "title": "Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pancreatic Cancer" ], "interventions": [ { "name": "N-803", "type": "BIOLOGICAL" }, { "name": "Aldoxorubicin HCl", "type": "DRUG" }, { "name": "PD-L1 t-haNK", "type": "BIOLOGICAL" }, { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "5-Fluorouracil", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "SBRT", "type": "PROCEDURE" }, { "name": "Irinotecan liposome", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "ImmunityBio, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 328, "start_date": "2020-07-21", "completion_date": "2026-05-31", "has_results": false, "last_update_posted_date": "2025-12-15", "last_synced_at": "2026-09-04T01:33:46.401Z", "location_count": 4, "location_summary": "El Segundo, California • Newport Beach, California • East Brunswick, New Jersey + 1 more", "locations": [ { "city": "El Segundo", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "East Brunswick", "state": "New Jersey" }, { "city": "Sioux Falls", "state": "South Dakota" } ], "official_url": "https://clinicaltrials.gov/study/NCT04390399" }, { "nct_id": "NCT03368963", "title": "TAS102 in Combination With NAL-IRI in Advanced GI Cancers", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Colorectal Adenocarcinoma", "Gastric Adenocarcinoma", "Metastatic Pancreatic Adenocarcinoma", "Non-Resectable Cholangiocarcinoma", "Stage IV Colorectal Cancer", "Stage IV Gastric Cancer", "Stage IV Pancreatic Cancer", "Stage IVA Colorectal Cancer", "Stage IVB Colorectal Cancer", "Stage III Colorectal Cancer", "Stage III Gastric Cancer", "Stage III Pancreatic Cancer", "Unresectable Digestive System Adenocarcinoma", "Unresectable Pancreatic Carcinoma" ], "interventions": [ { "name": "Nanoliposomal Irinotecan", "type": "DRUG" }, { "name": "Trifluridine and Tipiracil Hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 64, "start_date": "2018-01-30", "completion_date": "2025-11-28", "has_results": false, "last_update_posted_date": "2025-01-07", "last_synced_at": "2026-09-04T01:33:46.401Z", "location_count": 3, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03368963" }, { "nct_id": "NCT02231723", "title": "A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Pancreatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Pancreatic Adenocarcinoma" ], "interventions": [ { "name": "BBI608", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "MM-398", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sumitomo Pharma America, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 139, "start_date": "2014-08", "completion_date": "2020-06", "has_results": false, "last_update_posted_date": "2023-11-18", "last_synced_at": "2026-09-04T01:33:46.401Z", "location_count": 12, "location_summary": "Phoenix, Arizona • Atlanta, Georgia • Fort Wayne, Indiana + 9 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Fort Wayne", "state": "Indiana" }, { "city": "Goshen", "state": "Indiana" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT02231723" }, { "nct_id": "NCT02013336", "title": "Phase 1 Dose-escalating Study of MM-398 (Irinotecan Sucrosofate Liposome Injection) Plus Intravenous Cyclophosphamide in Recurrent or Refractory Pediatric Solid Tumors", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent or Refractory Solid Tumors", "Ewing Sarcoma", "Rhabdomyosarcoma", "Neuroblastoma", "Osteosarcoma" ], "interventions": [ { "name": "MM-398 (Irinotecan Sucrosofate Liposome Injection) plus cyclophosphamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "South Plains Oncology Consortium", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Months", "maximum_age": "20 Years", "sex": "ALL", "summary": "12 Months to 20 Years" }, "enrollment_count": 30, "start_date": "2013-12", "completion_date": "2023-12", "has_results": false, "last_update_posted_date": "2022-03-31", "last_synced_at": "2026-09-04T01:33:46.401Z", "location_count": 6, "location_summary": "Cincinnati, Ohio • Oklahoma City, Oklahoma • Dallas, Texas + 3 more", "locations": [ { "city": "Cincinnati", "state": "Ohio" }, { "city": "Oklahoma City", "state": "Oklahoma" }, { "city": "Dallas", "state": "Texas" }, { "city": "Houston", "state": "Texas" }, { "city": "Lubbock", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02013336" }, { "nct_id": "NCT03883919", "title": "Liposomal Irinotecan Plus 5-FU / LV Combined With Paricalcitol in Patients With Advanced Pancreatic Cancer Progressed on Gemcitabine-based Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pancreatic Cancer", "Pancreas Cancer", "Cancer of the Pancreas" ], "interventions": [ { "name": "5-FU", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Liposomal Irinotecan", "type": "DRUG" }, { "name": "Paricalcitol", "type": "DRUG" }, { "name": "Serum and plasma blood samples", "type": "PROCEDURE" }, { "name": "Tumor biopsy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2019-07-11", "completion_date": "2022-07-02", "has_results": false, "last_update_posted_date": "2022-10-05", "last_synced_at": "2026-09-04T01:33:46.401Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT03883919" } ] }